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The migration of the human pathogen Streptococcus pyogenes (group A streptococcus) from localized to deep
tissue sites may result in severe invasive disease, and sequestration of the host zymogen plasminogen appears
crucial for virulence. Here, we describe a novel plasminogen-binding M protein, the plasminogen-binding
group A streptococcal M protein (PAM)-related protein (Prp). Prp is phylogenetically distinct from previously
described plasminogen-binding M proteins of group A, C, and G streptococci. While competition experiments
indicate that Prp binds plasminogen with a lower affinity than PAM (50% effective concentration  0.34 M),
Prp nonetheless binds plasminogen with high affinity and at physiologically relevant concentrations of plas-
minogen (Kd  7.8 nM). Site-directed mutagenesis of the putative plasminogen binding site indicates that
unlike the majority of plasminogen receptors, Prp does not interact with plasminogen exclusively via lysine
residues. Mutagenesis to alanine of lysine residues Lys96 and Lys101 reduced but did not abrogate plasminogen
binding by Prp. Plasminogen binding was abolished only with the additional mutagenesis of Arg107 and His108
to alanine. Furthermore, mutagenesis of Arg107 and His108 abolished plasminogen binding by Prp despite the
presence of Lys96 and Lys101 in the binding site. Thus, binding to plasminogen via arginine and histidine
residues appears to be a conserved mechanism among plasminogen-binding M proteins.
The gram-positive bacterium Streptococcus pyogenes (group A
streptococcus [GAS]) is the major pathogenic agent of a wide
variety of skin and mucosal infections in humans. Current esti-
mates indicate that approximately 1.78 million new cases of se-
vere streptococcal infection emerge each year (5). A key feature
of invasive GAS infections is the ability of the organism to migrate
from cutaneous and mucosal surfaces to deep tissue sites, result-
ing in severe invasive disease. While the exact mechanisms by
which GAS cross host tissue barriers are yet to be fully elucidated,
sequestration of plasminogen by GAS is being increasingly impli-
cated in the pathogenesis of this organism (32). Indeed, for a
subset of GAS isolates, acquisition of plasminogen via cell surface
receptors appears to be crucial for virulence (6, 30).
Plasminogen is a single-chain glycoprotein found in plasma
and extracellular fluids at concentrations of approximately 2
M (8). Specific mammalian plasminogen activators cleave
plasminogen at a single site (Arg560-Val561), resulting in the
formation of the two-chain plasmin molecule, which contains a
serine protease active site in the C-terminal region. Plasmin-
(ogen) typically interacts with its ligands via lysine binding sites
located in the five kringle domains of the N terminus of plas-
minogen (21). Plasmin(ogen) receptors and activators have
been found to be expressed by a large number of bacteria,
including group A, C, and G streptococci (15). In addition to
the secreted nephritogenic plasminogen-binding protein (22),
three cell surface-expressed GAS plasminogen-binding pro-
teins have been identified. These are streptococcal surface
enolase (SEN) (18), glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) (4, 19), and the plasminogen-binding group A
streptococcal M protein (PAM) (3). Furthermore, the secreted
protein streptokinase enables GAS to activate plasminogen to
plasmin (15). Plasmin has the ability to degrade fibrin clots,
connective tissue, and the extracellular matrix (8, 21). Thus,
sequestration of this proteolytic system by GAS may have
significant pathological consequences in the host.
Coded for by the emm gene, M protein is one of the major
virulence factors of GAS. The emm family of genes consists of
emm, mrp, and enn genes (12). The N termini of M proteins
consist of a highly variable region, followed by a series of
repeat domains designated a, b, c, and d. The number and type
of repeats vary significantly between different M proteins (7,
16). Here we describe a novel, high-affinity plasminogen-bind-
ing M protein, the PAM-related protein Prp. Associated with
an S. pyogenes emm 98.1 strain isolated from a severe invasive
infection and which displays high levels of cell surface plas-
minogen binding (17), Prp is phylogenetically distinct from
previously characterized plasminogen-binding M proteins. Us-
ing site-directed mutagenesis we show that, like PAM, Prp
binds plasminogen via arginine and histidine residues, rather
than lysine residues, which commonly mediate the interaction
of plasminogen with its many other receptors.
MATERIALS AND METHODS
Bacterial strains and culture methods. Group A streptococcal strains were
grown on horse blood agar plates (American Diagnostica) or cultured overnight
at 37°C in Todd-Hewitt broth (Difco Laboratories) containing 1% yeast extract.
All streptococcal strains used in this study were collected from the Northern
Territory of Australia and have been described previously (17, 26). Escherichia
coli INVF containing pCR2.1/Prp constructs (17) or E. coli TOP10 containing
expression plasmids was grown on Luria-Bertani (LB) agar plates or cultured in
LB broth supplemented with ampicillin (100 g/ml) as described previously (25).
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Plasmid DNA was extracted for PCR and DNA sequence analysis using the
Wizard Plus SV DNA purification kit (Promega).
Phylogenetic analysis. In order to characterize the evolutionary relationships
between Prp and naturally occurring variants of the PAM protein, the full amino
acid sequences of 12 previously identified PAM proteins and Prp (17) were
aligned using ClustalW (31). Evolutionary gene trees were then estimated using
MrBayes version 3.1 (13, 24). For the MrBayes analysis, four simultaneous chains
were run, with trees sampled every 100 generations for a total of 500,000 gen-
erations. Plots of likelihood scores against generation were used to identify when
the analysis had reached stationarity. Trees sampled prior to stationarity (the
first 40 trees) were discarded. The amino acid model was empirically chosen by
MrBayes, using the prset aamodelpr  mixed command. This permits jumping
between nine alternative amino acid substitution models. The WAG model (33)
was empirically chosen by MrBayes. The majority rule consensus of all trees
generated after stationarity was used to estimate the posterior probabilities of
the various nodes in the most likely tree.
DNA sequence analysis, expression, and purification of recombinant M pro-
teins. The Prp gene from GAS strain NS88.2 had previously been cloned into the
vector pCR2.1 (17). Primer sequences used for DNA sequence analysis are
available upon request. DNA sequence reactions were undertaken using termi-
nator ready reaction mix (PE Applied Biosystems). DNA sequencing gels were
prepared as per the manufacturer’s instructions and electrophoresed using a
Perkin-Elmer ABI PRISM 377 sequencer. Sequence data were analyzed using
ABI Prism DNA sequencing analysis software (Perkin-Elmer). To facilitate
functional analysis, Prp was cloned into the expression vector pGEX-2T essen-
tially as previously described (26). Briefly, the Prp gene was amplified from a
pCR2.1 construct by using Pfu polymerase (Stratagene). PCR cycling parameters
consisted of 30 cycles of 97°C, 55°C, and 72°C for denaturation, annealing, and
extension reactions, respectively. Amplicons were cloned into pGEX-2T (29),
resulting in an N-terminal fusion with glutathione S-transferase, and constructs
were transformed into E. coli TOP10 (Invitrogen) by standard procedures (25).
The presence of both a His6 tag and a glutathione S-transferase tag on the
recombinant protein enabled purification by two methods. DNA sequence anal-
ysis was used to confirm the lack of PCR errors in the cloned amplification
product. Recombinant proteins were expressed and purified as described previ-
ously (26). Each step of the protein purification process was monitored by 12%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analy-
sis (14), with protein visualized using Coomassie blue R250 staining.
Site-directed mutagenesis. Sequence alignment of Prp with other plasminogen-
binding M proteins identified a potential plasminogen binding site within the mol-
ecule. In order to confirm the role of specific residues within this region in the
interaction of Prp with plasminogen, site-specific mutations were introduced into the
putative binding site. The wild-type pGEX-2T construct (100 ng) was used as tem-
plate DNA to create site-directed mutants with the QuikChange site-directed mu-
tagenesis kit (Stratagene). PCR mixtures consisted of 1 PFU reaction buffer
(Stratagene), 0.25 mM deoxynucleoside triphosphates (Boehringer Mannheim, Ger-
many), 2.5 U of PfuUltra polymerase (Stratagene), and 125 ng of each primer, made
up to a volume of 50 l with distilled water. Oligonucleotide primers (Sigma-
Aldrich) were designed as per the manufacturer’s instructions (Stratagene). In gen-
eral, primers consisted of sequence encoding the desired mutation, flanked on either
side by 15 nucleotides of wild-type sequence. The specific primer sequences are
available upon request. For site-directed mutants containing more than two muta-
tions not encoded by a single primer, alanine residues were sequentially introduced
using previously mutated DNA as a template. Following an initial denaturation step
(95°C, 30 s), PCR cycling parameters consisted of 16 cycles of 95°C for 30 s, 55°C for
1 min, and 68°C for 10 min. An additional 7-min extension at 55°C was then
performed. PCR was conducted with a Cooled Palm 96 thermocycler (Corbett
Research). Nonamplified template DNA was removed by incubation of reaction
mixtures for 1 h at 37°C following the addition of DpnI (10 U/50-l reaction
mixture). E. coli TOP10 (Invitrogen) was transformed with 150 ng of DpnI-digested
PCR product by standard procedures (25).
CD spectroscopy. To highlight potential variation in protein secondary struc-
ture as a result of site-directed mutagenesis, far-UV circular dichroism (CD)
spectra were obtained for both wild-type and mutant recombinant proteins. CD
spectra were acquired using a Jasco J-810 spectropolarimeter (Jasco, Canada) at
room temperature. CD spectral data were recorded from 190 to 250 nm in a
1-cm-path-length cell containing 1.5 ml of protein solution at a concentration of
0.04 mg/ml in 10 mM sodium phosphate buffer (pH 7.4). Recorded data repre-
sent the averages of six scans, corrected for buffer baseline. Molar residue
ellipticity ([]) was calculated using the following formula: []    100 
molecular weight/concentration (mg/ml)  distance  number of amino acids
(28). The percentage of -helices was estimated from the ellipticity at 222 nm
using the following formula: percent -helix  (222 nm  4,800)/45,400 (20).
Plasminogen purification and labeling. Glu-plasminogen, the circulating form
of plasminogen, was purified from human plasma by using lysine Sepharose 4B
affinity chromatography as described previously (1, 26). Purified plasminogen was
biotinylated by the addition of 10% (vol/vol) 1 M NaHCO3 (pH 9), and a 40 molar
excess of biotin-X-N-hydroxysuccinimide in dimethyl sulfoxide (Sigma-Aldrich). The
reaction mixture was incubated at 4°C overnight with mixing. Free biotin was sep-
arated from biotinylated plasminogen by PD-10 gel filtration chromatography
(Amersham Biosciences).
Plasminogen binding analysis. Solid-phase plasminogen binding assays were
performed in order to assess both the affinity of Prp for plasminogen and the
impact of introduced mutations on protein function, essentially as previously
described (26). Ninety-six-well microtiter plates (Greiner Bio-one, Germany)
were coated with 150 nM recombinant protein (50 l in 0.1 M NaHCO3) at 4°C
overnight. Following three washes with PiNT (50 mM Na2HPO4, 150 mM NaCl,
0.05% Tween 80, pH 7.5), plates were blocked with 50 l of blocking solution
(1% skim milk powder in PiNT) for 1 h at 37°C. Wells were washed as described
above, and 500 nM biotinylated glu-plasminogen was diluted in a threefold
titration across the plate with blocking buffer in the presence or absence of a
50-fold molar excess of unlabeled glu-plasminogen. Plasminogen was allowed to
bind to immobilized proteins for 2 h at room temperature. For competition
assays, decreasing concentrations of unlabeled fluid-phase PAMNS13 (25 M to
0.14 nM) or wild-type Prp were allowed to compete with immobilized proteins
for binding to biotinylated glu-plasminogen. Competitor was titrated threefold
across the microtiter plate prior to the addition of biotinylated glu-plasminogen
to all wells, at a final concentration of 500 nM. The assay mixture was incubated
for 2 h at room temperature. Following the plasminogen incubation step, micro-
titer plates were washed three times, and 50 l of neutravidin conjugated to
horseradish peroxidase (Progen, Australia) diluted 1:5,000 with blocking solution
was added to all wells and incubated for 2 h at room temperature. After five
washes with PiNT, the reactions were developed by the addition of 50 l o-
phenylenediamine (Sigma-Aldrich) substrate (8 mM Na2HPO4 [pH 5.0], 2.2 mM
o-phenylenediamine, 3% H2O2). Color development was stopped by the addition
of 50 l of 10 M hydrochloric acid, and the plates were read at 490 nm using a
Spectramax 250 plate reader (Molecular Devices).
Data were normalized against the highest and lowest absorbance value for
each assay, and nonlinear regression analysis was performed using GraphPad
Prism (v4.00; GraphPad Software, CA). For the calculation of equilibrium bind-
ing dissociation constants (Kd), a one- versus two-site binding analysis was con-
ducted and the best-fit curve fitted to the data. For competition experiments, a
one-site competition curve was fitted to the data, from which the effective
concentration of competitor required to inhibit binding by 50% was calculated.
Statistical analysis. For plasminogen binding experiments, a one-way analysis
of variance was initially used on all data, followed by an unpaired t test with
Welsch’s correction to determine if there was any significant difference in the Kd
values obtained for various proteins in this study.
Nucleotide sequence accession number. The Prp gene sequence has been
submitted to the NCBI database and assigned GenBank accession number
AY351856.
RESULTS
Phylogenetic analysis. Isolated from a bacteremia infection,
GAS strain NS88.2 encodes a PAM-related M protein (Prp)
that is only 66.4% identical to PAM if the conserved C-repeat
domain is excluded. Phylogenetic analysis of Prp and a subset
of group A, C, and G streptococcal plasminogen-binding M
proteins indicates that Prp is a phylogenetically distinct mole-
cule (Fig. 1). All of the PAM variants share a common ancestor
that does not include Prp, suggesting that Prp diverged early
during the evolution of PAM and the PAM-related proteins.
Plasminogen binding analysis. In order to confirm that Prp
functions as a high-affinity plasminogen receptor, plasminogen
binding analysis of recombinant Prp was undertaken. Recom-
binant Prp was expressed and purified using glutathione-aga-
rose and Ni-nitrilotriacetic acid agarose affinity chromatogra-
phies. Recombinant PAMNS13 and the NS696 M1 protein were
also purified for use as positive and negative controls, respec-
tively, in plasminogen binding studies (Fig. 2A). PAMNS13 is
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100% identical to the prototype PAM protein in the a1 and a2
repeat region and has previously been shown to interact with
glu-plasminogen with high affinity, while the NS696 M1 protein
displays only nonspecific binding affinity for plasminogen (26).
Ligand blot analysis indicated that the 43-kDa recombinant
Prp molecule interacts with biotinylated glu-plasminogen (Fig.
2B). The interaction between recombinant Prp and glu-plas-
minogen was further characterized using solid-phase plasmin-
ogen binding assays. Immobilized Prp bound plasminogen in a
dose-dependent fashion, and saturable binding was achieved
with 500 nM plasminogen after 2 h (Fig. 3A). This is compa-
rable to the binding of plasminogen by the positive control
protein PAMNS13 (Fig. 3B). Only nonspecific binding was
found for the negative control NS696 M1 protein (Fig. 3C).
Best-fit nonlinear regression analysis determined the equilib-
rium dissociation constant (Kd) for the interaction of Prp with
glu-plasminogen to be 7.6 nM. The interaction between Prp
and plasminogen is therefore significantly lower than that of
PAMNS13 with plasminogen (Kd  1.6 nM; P  0.02). To
further explore the relative affinity of Prp for plasminogen
compared to PAM, Prp binding to biotinylated plasminogen
was competed with various concentrations of unlabeled fluid-
phase PAMNS13. The effective concentration of competitor
required to inhibit plasminogen binding by 50% was found to
be 0.34 M, as determined by fitting a one-site competition
curve (Fig. 4). This confirms that Prp has a lower affinity for
FIG. 1. Phylogeny generated by Bayesian analysis of the amino acid
sequences of 13 PAM genes (PAMNS13, GenBank accession no.
AY351851; PAMNS455, GenBank accession no. AY351857; PAMNS265,
GenBank accession no. AY351855; PAMNS223, GenBank accession no.
AY351854; PAMNS253, GenBank accession no. AY351853; PAMNS53,
GenBank accession no. AY351852; PAMNS32, GenBank accession no.
AY351850; PAMNS50.1, GenBank accession no. AY351849; PAMNS59,
GenBank accession no. AY351848; PAMNS1133, GenBank accession
no. AY351847; PAMNS10, accession no. GenBank AY351846; PAMNS221,
GenBank accession no. DQ136319; NS696 M1 protein, GenBank acces-
sion no. AY351858; and Prp, GenBank accession no. AY351856). MLC36
(GenBank accession no. Z32677) and MLC72 (GenBank accession no.
Z32678) are plasminogen-binding M protein sequences from group C and
group G streptococci, respectively (2). The M1 (11) and NS696 M1 pro-
tein sequences were included as outgroups.
FIG. 2. SDS-PAGE and ligand blot analysis of recombinant M
proteins. (A) SDS-12% polyacrylamide gel showing the purified re-
combinant proteins PAMNS13 (lane 1), Prp (lane 2), and NS696 M1
(lane 3). Molecular mass markers are given in kilodaltons. (B) Ligand
blot analysis employing biotinylated glu-plasminogen of purified re-
combinant proteins PAMNS13 (lane 1), Prp (lane 2), and NS696 M1
(lane 3). Molecular mass markers are given in kilodaltons.
FIG. 3. Saturation binding analysis of biotinylated glu-plasminogen
binding to immobilized recombinant proteins. Biotinylated glu-plas-
minogen binding to immobilized recombinant proteins Prp (A),
PAMNS13 (B), and NS696 M1 protein (C) was measured in the absence
(, total binding) and presence (}, nonspecific binding) of a 50-fold
molar excess of unlabeled glu-plasminogen. Specific binding (■) was de-
termined by subtracting nonspecific binding from total binding at each
concentration. A one-site hyperbolic binding function was fitted to the
data (P 	 0.05), from which the binding dissociation constants were
determined. Error bars represent the standard errors of the means.
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plasminogen than PAM. Nonetheless, the binding of plasmin-
ogen by Prp with a Kd of 7.6 nM represents a high-affinity,
physiologically relevant interaction.
Binding site characterization. The major site of variation
between Prp and the prototype PAM protein lies between
residues 29 and 100 in the N terminus of Prp. This sequence
includes a region of 21 amino acids, with 52% identity to the
plasminogen binding site of PAM (17), which may function as
a plasminogen binding domain within the Prp molecule. This
putative plasminogen binding domain appears to consist of a
single binding site comprised of 21 amino acids (Fig. 5A), in
contrast to the a1 and a2 repeats found to mediate plasmino-
gen binding by PAM (3). In order to confirm the role of this
potential binding site in the interaction of Prp with plasmino-
gen and to identify the specific residues which mediate binding,
a series of site-directed mutants in which selected binding site
residues were mutated to alanine was constructed. The bind-
ing-site sequences of the site-directed mutants are given in Fig.
5B. Plasminogen typically binds to internal and C-terminal
lysine residues, and thus lysine residues Lys96 and Lys101 were
mutated to alanine. Additionally, PAM is able to mediate
high-affinity plasminogen binding via internal residues Arg101,
His102, Arg114, and His115 (27). Therefore, residues Arg107 and
His108 were also selected for mutagenesis.
The impact of mutations in the plasminogen binding domain
of Prp on protein structure was analyzed using far-UV CD
spectroscopy. All site-directed mutants used in this study were
found to have a CD emission spectrum similar to that of
wild-type Prp, displaying two characteristic minima at approx-
imately 210 nm and 220 nm and a maximum peak at 190 nm
(data not shown). This is similar to the CD spectra of other
streptococcal M proteins, which are coiled-coil -helical pro-
teins (20). Thus, even after mutagenesis these proteins appear
to maintain an -helical secondary structure. Additionally, for
all proteins the two minima are of a similar magnitude, which
is indicative of coiled-coil proteins (9, 10). The percent -
helicity ranged from 37% to 43%. These data confirm that these
proteins are structurally similar and that site-directed mutagene-
sis has resulted in minimal changes to secondary structure.
In order to determine the impact of site-directed mutagen-
esis on plasminogen binding by Prp, plasminogen binding anal-
ysis was conducted. Wild-type Prp and Prp[K96 K101] both
interacted with biotinylated glu-plasminogen in a ligand blot
analysis. No interaction with Prp[K96K101R107H108] or Prp
[R107H108] was seen (Fig. 6). This suggests that the interaction
FIG. 6. SDS-PAGE and ligand blot analysis of Prp site-directed
mutants. (A) SDS-12% polyacrylamide gel showing the purified re-
combinant proteins Prp (lane 1), Prp[K96K101R107H108] (lane 2),
Prp[K96K101] (lane 3), and Prp[R107H108] (lane 4). Molecular mass
markers are given in kilodaltons. (B) Ligand blot analysis employing
biotinylated glu-plasminogen of purified recombinant proteins Prp
(lane 1), Prp[K96K101R107H108] (lane 2), Prp[K96K101] (lane 3), and
Prp[R107H108] (lane 4). Molecular mass markers are given in kilodaltons.FIG. 4. Competition of glu-plasminogen binding to immobilized
recombinant Prp with fluid-phase PAMNS13. Binding of biotinylated
glu-plasminogen to immobilized Prp was measured in the presence of
various concentrations of unlabeled fluid-phase PAMNS13. Data points
are the mean values of triplicate readings, with error bars indicating
standard errors of the means. One-site competition analysis was used
to determine the concentration of PAMNS13 required to inhibit binding
of biotinylated glu-plasminogen by 50%.
FIG. 5. (A) Translated DNA sequences of the plasminogen-binding region (a1/a2 repeats) of the prototype PAM binding site with PAMNS13
and a putative 21-amino-acid residue Prp plasminogen-binding site. *, residues identical to those of the PAM sequence; -, gaps in the alignment.
(B) Alignment of the plasminogen binding domain of wild-type Prp with those of the three site-directed mutants constructed in this study. Mutated
residues are indicated in boldface.
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of Prp with glu-plasminogen is mediated by residues Arg107
and His108. To further characterize the role of these residues in
plasminogen binding and to determine the specificity of
Prp[K96K101] plasminogen binding, solid-phase plasminogen
binding assays were conducted using the site-directed mutant
Prp proteins. None of the site-directed mutants interacted in a
specific, saturable fashion with 500 nM plasminogen (Fig. 7).
Prp[K96K101] approached but did not reach saturation (Fig. 7).
Indeed, in the presence of 500 nM plasminogen, wild-type Prp
was found to interact specifically with approximately 80% of
the available labeled plasminogen. In contrast, Prp[K96K101]
shows only 50% specific binding at the same plasminogen
concentration. This suggests that this protein is still able to
mediate a lower-affinity interaction with plasminogen, in spite
of the absence of lysine residues. Only nonspecific binding was
found for site-directed mutants Prp[K96K101R107H108] and
Prp[R107H108]. Thus, it appears that residues Arg107 and
His108 are indispensable for mediation of the high-affinity in-
teraction of Prp with plasminogen.
DISCUSSION
Prp functions as a high-affinity receptor for glu-plasminogen,
as evidenced by the plasminogen binding data presented here.
To date, PAM has been reported to have the highest affinity of
the known GAS plasminogen receptors for glu-plasminogen
(Kd 
 1 nM) (3, 26). While the interaction of Prp with glu-
plasminogen is of a lower affinity than that of PAM (Kd  7.8
nM), Prp binds plasminogen specifically. Furthermore, circu-
lating concentrations of glu-plasminogen are approximately 2
M, and thus the interaction of Prp with plasminogen is within
physiologically relevant concentrations of the zymogen (8).
Plasminogen typically binds to receptors via C-terminal or
internal lysine residues, as exemplified by the previously char-
acterized GAS plasminogen receptors SEN and GAPDH.
Binding of plasminogen to SEN occurs via residues Lys434 and
Lys435 at the C terminus of the SEN molecule, while binding of
plasminogen to GAPDH occurs via the C-terminal lysine
Lys334 (4, 18). In contrast, plasminogen binding to PAM has
been attributed to internal lysine residues Lys98 and Lys111(3,
34, 35). However, it has recently been demonstrated that PAM
mediates its interaction with plasminogen via arginine and
histidine residues within two internal repeat domains (27).
Mutation of lysine residues within a putative Prp plasminogen
binding site (Lys96 and Lys101) did not result in the abrogation
of plasminogen binding. While mutation of these residues re-
duced the affinity of Prp for plasminogen, binding was fully
eliminated only following the mutation of residues Arg107 and
His108 to alanine. Indeed, the finding that plasminogen binding
was eliminated even in the presence of lysine residues high-
lights the role of residues Arg107 and His108 in mediating the
interaction of Prp with plasminogen. Changes in plasminogen
binding by site-directed mutants do not appear to result from
protein structural changes, as far-UV CD analysis of site-di-
rected mutants indicates that these molecules are structurally
similar to the wild-type Prp. The percent -helicity for mutants
reported here was between 37% and 43%. CD analysis of other
streptococcal M proteins has found them to contain between
23% and 70% -helices (20). This demonstrates that despite
the phylogenetic differences between PAM and Prp, both in-
teract with plasminogen via a common mechanism which is
distinct from the interaction of other plasminogen-binding pro-
teins.
X-ray crystallography analysis of a 30-amino-acid peptide
has shown that arginine and histidine residues, when correctly
presented in an alpha-helical molecule, are able to make nu-
merous salt bridge and hydrophobic electrostatic interactions
with recombinant kringle 2 of plasminogen, forming a pseudo-
ligand similar to the lysine analogue ε-amino caproic acid (23).
It is conceivable that the residues Arg107 and His108 within Prp
interact with plasminogen in a similar fashion. Thus, the bind-
ing site of Prp can be localized to a single domain within the N
terminus of the protein encompassing residues Arg107 and
His108.
Recent findings that the acquisition of plasminogen by S.
pyogenes may be crucial for the virulence of certain strains of
GAS (6, 30), and the ability of multiple GAS proteins to
facilitate this process, necessitate a deeper understanding of
the mechanisms via which GAS interacts with plasminogen.
This study identifies a novel plasminogen-binding M protein
which interacts with plasminogen via arginine and histidine
residues within a single binding domain. While lysine residues
within this domain do appear to contribute partially to this
interaction, they are not the primary residues by which plas-
minogen binds, in contrast to findings for other GAS plasmin-
ogen receptors. The finding that multiple M proteins with
plasminogen binding ability have evolved separately is indica-
tive of the selective advantage that plasminogen binding con-
fers upon GAS and supports the suggestion that interaction
with the host plasma protein plasminogen may be important
for the virulence of certain strains of GAS. Plasminogen bind-
ing by arginine and histidine residues has, to date, been re-
ported only for GAS plasminogen-binding M proteins. This
interaction may represent a novel way in which the bacterium
binds to the low-affinity kringle 2 of plasminogen, thereby
avoiding competition with other abundant host proteins and
inhibitors. The apparent advantage conferred on GAS by its
ability to interact with the host plasminogen activation system
FIG. 7. Specific binding of biotinylated glu-plasminogen to immo-
bilized recombinant proteins Prp (■), Prp[K96K101R107H108] (),
Prp[K96K101] (), and Prp[R107H108] (F). Specific binding was deter-
mined by subtracting nonspecific binding from total binding at each
concentration. A one-site hyperbolic binding function was fitted to the
data (P 	 0.05), from which the binding dissociation constants were
determined. Error bars represent the standard errors of the means
(n  3).
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via a number of receptors has widespread implications for both
the study and treatment of GAS pathogenesis and infection.
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